The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - VBL Therapeutics (VBLT) and Celsus Therapeutics (CLTX) each announced disappointing Phase 2 results for their drug candidates in inflammatory indications.
Read nowRecap - The range that had dominated trading in the S&P 500 for all of 2015 (which we wrote about last weekend) finally came to an end this Friday (the … Continue Reading
Read nowInsights - In healthcare and pharmaceutical news this week, famed predictor of the subprime mortgage crisis and hedge fund manager Kyle Bass has taken aim at the … Continue Reading
Read nowInsights - Genzyme (of Sanofi [SNY]) announced on Wednesday a collaboration with the private gene therapy company Voyager Therapeutics.
Read nowResearch - In early December we published Mr. Fink’s deep-dive on Innate Pharma (IPH.PA) (IPHYF), explaining why we wanted to own the stock in 2015.
PremiumInsights - Pfizer (PFE) announced plans to buy injectable generics & biosimialar developer Hospira (HSP) at $90/share, for an enterprise value of $17 billion. Hospira closed Wednesday at $64.80.
Read now
